HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Barcy, S. Articles by Corey, L. Search for Related Content PubMed PubMed Citation Articles by Barcy, S. Articles by Corey, L.

Herpes Simplex Inhibits the Capacity of Lymphoblastoid B Cell Lines to Stimulate CD4⁺ T Cells¹

Serge Barcy^2,* and Lawrence Corey^3,*,,

Departments of ^* Laboratory Medicine and Medicine, University of Washington, Seattle, WA 98195; and Program in Infectious Diseases, Fred Hutchinson Cancer Research Center, Seattle, WA 98109

	Abstract

Top Abstract Introduction Materials and Methods Results Discussion References

 
HSV establish a lifelong persistent infection in their host even among immunocompetent persons. The viruses use a variety of immune evasion strategies, presumably to assist persistent replication in the human host. We have observed that infection of human B lymphoblastoid cells (B-LCL) by HSV resulted in a strong inhibition of their ability to induce CD4⁺ T cell clone proliferation and cytokine secretion. This inhibitory effect occurs in a variety of both HSV- and HIV-specific clones from three different patients. The inhibition is observed when the Ag is provided either as a soluble protein or as a synthetic peptide and is not associated with detectable down-modulation of the MHC class II molecules or costimulatory molecules. Expression of the HSV-1 unique sequence 1 gene (US1) is necessary and sufficient to induce this inhibition of APC function. US1 gene expression also made B-LCL less susceptible to CD4⁺ T cell-mediated lysis. These data indicate a novel immune evasion strategy by HSV-1 in which Ag-processing cells that become infected by HSV-1 are inhibited in their ability to induce subsequent CD4⁺ T cell activation.

	Introduction

Top Abstract Introduction Materials and Methods Results Discussion References

 
Herpes simplex virus type 1 (HSV-1) and type 2 (HSV-2) are common human pathogens that first infect and replicate in epithelial cells of mucosal membranes and then spread via sensory neurons into ganglia, where they establish a chronic latent infection (1). Reactivation of HSV from neurons and reinfection of the mucosal tissues occurs intermittently, causing recurrent cutaneous lesions despite the presence of relatively high titers of neutralizing Ab (2) and detectable HSV-specific T cell response (3). Antigenic variation is not utilized by HSV as a mechanism of persistence. Several mechanisms have been identified by which HSV-1 inhibits recognition by CD8⁺ T cells. The HSV-1 infected cell protein (ICP)⁴ 47 blocks the peptide transporter (TAP), preventing access of antigenic peptides into the class I pathway (4). HSV-1 has also been shown to prevent the transport of MHC class I molecules to the cell surface (5) and can block CTL-induced Ag-dependant apoptosis (6). However, a wide variety of evidence also points to the critical need for CD4⁺ T cells in maintaining effective and persistent cytotoxic T lymphocyte responses (7). CD4⁺ T cells are the initial infiltrating cells in herpetic lesions and secrete a wide variety of cytokines (8). Release of cytokines by CD4⁺ cells plays a major role in activation of CD8⁺ T cells, activation of B lymphocytes and subsequent production of specific antiviral Ab, and activation of nonspecific inflammatory cells such as NK and macrophages. Moreover, CD4⁺ lymphocytes constitute the predominant source of IFN- from blood mononuclear cells of patients with recent recurrent herpetic lesions (9). In vitro, IFN- partially reverses the down-regulation of MHC class I after HSV infection of epidermal cells and induces MHC class II expression (10). As such, we sought to evaluate whether HSV has developed an immune escape mechanism that could block recognition of HSV-infected cells by CD4⁺ T cells. The HSV-1 ICP22 the product of the unique sequence 1 (US1) gene, is a nucleotidylated and phosphorylated protein with properties of a transcriptional factor required for the expression of a subset of late viral genes (11). Our current findings demonstrate that HSV-1 US1 gene expression in lymphoblastoid APC results in a dramatically reduced ability to stimulate CD4⁺ T cell clone proliferation and cytokine secretion.

	Materials and Methods

Top Abstract Introduction Materials and Methods Results Discussion References

 
Viruses and cells

HSV-1 (strain F), HSV-1 US1 deletion mutant (R325), HSV-1 unique sequence 3 (US3) deletion mutant (R7041), and respective repaired viruses (R4968, R7036) (12), HSV-1 unique sequence 12 (US12) deletion mutant (HV1.102), and HSV-2 (strain 186) were all grown and titered in Vero cells. HSV-2 ICP4 deletion mutant (hr259) (13) was propagated and titered on E5 cells.

All cell lines were maintained in complete medium, consisting of RPMI 1640 supplemented with antibiotics and 10% heat-inactivated bovine serum (Gemini Bio-Products, Woodland, CA). The study protocol was approved by the University of Washington Institutional Review Board.

EBV-transformed lymphoblastoid cell lines (B-LCL) and HSV-specific T cell clones EB47, EB13, ES21, and ES37 were derived as previously described (14). The T cell clones were established in culture from a skin lesion biopsy (clones EB47 and EB13) or a blood sample (clone ES21 and ES37) obtained from immunocompetent patients with genital HSV-2 infection. The clonality of each T cell line was assessed by PCR for TCR V gene expression (Clontech Laboratories, Palo Alto, CA, ). HIV-specific T cell clone 9G8 has been previously described (15).

Plasmid expression vectors

The full coding sequence of US1 was amplified by PCR from HSV-1 viral DNA (strain F) using primers (5'-GGTGGTACCCGTTTTCAGGATGGCCGACATTTC-3') and (5'-GCCGGATCCTCCGCCCTTCCCGCCATTAA-3'). After a 5-min incubation at 94°C, the PCR was cycled 35 times at 94°C for 30 s, 60°C for 30 s, and 68°C for 3 min followed by a final extension at 68°C for 7 min using the High Fidelity PCR System (Boehringer Mannheim, Indianapolis, IN). The PCR product was cloned in the pCRII TOPO vector and sequenced using dye deoxy-terminator (Applied Biosystems Prism; Applied Biosystems, Foster City, CA). The US1 gene was then transferred in two fragments, XhoI-HindIII of 0.9 kb and HindIII-BamHIII of 0.5 kb, into pNS vector (16) opened by XhoI-BamHI.

Transfection

B-LCL were transfected using LipofectANIME (Life Technologies, Rockville, MD) according to the manufacturer’s protocol. Briefly, cells (3 x 10⁶) were washed in serum-free RPMI 1640 and resuspended in 0.8 ml of Optimem (Life Technologies). Ten micrograms of purified plasmid DNA was mixed with 20 µl of LipofectAMINE in 0.2 ml of Optimem, incubated for 45 min at room temperature, and added to the B-LCL suspension in one well of a six-well plate. The cells were then incubated in a 5% CO₂ humidified atmosphere for 5 h. After 24 h, the cells were washed and resuspended in fresh complete RPMI 1640 medium. G418 sulfate (Calbiochem, La Jolla, CA) was added on day 3 at 1 U/ml.

Ag-specific proliferation

B-LCL were infected for 18 h with the relevant virus at a multiplicity of infection (MOI) of 10, then washed and counted. After irradiation (10,000 rad), stimulator cells (10⁵ cells/ml) were mixed with T cell clones (5 x 10⁵ cells/ml) in the presence of 1 µg/ml of purified HSV glycoprotein B (gB) or glycoprotein (gD). Virus UV inactivation was achieved by exposing viral inoculum to an UV light source (10 cm from a GTO38 bulb) for 10 min.

In some experiments, B-LCL were incubated for 1 h at 37°C before infection in the presence of gB or gD (1 µg/ml). Transfected B-LCL were irradiated (10,000 rad) and mixed at various dilutions with T cell clones in the presence of 1 µg/ml of either gB or gD.

For peptide stimulation, irradiated cells were incubated with 10 µg/ml of aa 571–590 from HIV-1 envelope peptide epitope (VWGIKQLQARVLAVERYLKD) for 1 h on ice before being washed, irradiated, and used as stimulatory cells at various dilutions.

After 3 days of culture, cells were pulsed for 16 h with 0.5 µCi of [³H]thymidine (NEN, Boston, MA). [³H]Thymidine incorporation was determined with a liquid scintillation counter. Proliferation of T cell clones was performed in triplicate wells.

Cytokine titration

After 24-h culture, supernatants from triplicate wells were pooled and tested for the presence of cytokines. Measurements of human IL-2 and IFN- were analyzed using a sandwich ELISA. Samples were tested in duplicate. The coefficient of variation was always <10%. Matched pair Abs were purchased from R&D Systems (IL-2; Minneapolis, MN) and Endogen (IFN-; Woburn, MA). The lowest detection limit for the IL-2 assay is 5 and 0.5p g/ml for the IFN- assay.

Cytotoxicity assay

Standard chromium release assays were performed. Briefly, autologous target B-LCL were infected for 18 h with relevant virus at an MOI of 10 in the presence of 100 µCi of ⁵¹Cr (NEN), washed, and counted. CD4⁺ T cell clones and ⁵¹Cr-labeled target B-LCL were cultured together using various E:T ratios. After 4 h at 37°C, 30 µl of supernatant was removed and counted in Lumaplates with a TopCount scintillation counter (Packard, Meriden, CT).

For redirected cytotoxicity assay, P815 FcR-positive mouse mastocytoma cells were infected at an MOI of 10 for 18 h in the presence of ⁵¹Cr. The labeled target cells were then mixed with T cells at various E:T ratios. Purified OKT3 Ab was added at a final concentration of 1 µg/ml.

Percent specific lysis was calculated as: 100 x [(cpm released with effectors) - (cpm released alone)]/[(cpm released by detergent) - (cpm released alone)]. Spontaneous release was always <20% of maximum release.

Flow cytometry

Standard procedures were used for flow cytometric analysis. B-LCL (1 x 10⁶) were resuspended in PBS containing 1% FBS and 0.1% NaN₃. The cells were incubated at 4°C for 30 min with either primary or PE-labeled mAbs of the appropriate specificity. When relevant, cells were washed and incubated for an additional 30 min at 4°C with PE-labeled goat anti-mouse Ig (Sigma, St. Louis, MO).

MHC class II molecule expression was evaluated using mAb B7.21 specific for the HLA-DP framework determinant, mAb SPV-L3 specific for the HLA-DQ framework, and mAb L-243 specific for the HLA-DR framework (14). Abs specific for CD80 and CD86 molecules were purchased from Becton Dickinson (Mountain View, CA).

Cytoplasmic staining was performed as previously described (17). Cells were fixed with 3.7% paraformaldehyde and permeabilized using a 0.01% Nonidet P-40 solution in PBS. The cells were then incubated with the rabbit antiserum R77 (12) and stained with an FITC-labeled goat anti-rabbit antiserum (Vector Laboratories, Burlingame, CA).

Relative fluorescence intensities were measured with a FACSCalibur (Becton Dickinson). Data were analyzed using WinMDI software (Joseph Trotter, The Scripps Clinic, La Jolla, CA).

	Results

Top Abstract Introduction Materials and Methods Results Discussion References

 
HSV-1 infection of B-LCL inhibits Ag-specific T cell activation

Human B cells immortalized by EBV (B-LCL) have been widely used as APC. We sought to evaluate whether B-LCL infected by HSV-1 were impaired in their ability to efficiently stimulate CD4⁺ T cell clones. Initially, we used HSV-specific CD4⁺ T cell clones that were isolated from two different donors with genital herpes. Two clones, EB47 and EB13, were derived from the expansion of lesion-infiltrating T cells from a skin biopsy of an HSV-2 buttock lesion. The clones were CD3⁺/CD4⁺/CD8^- and were determined to recognize the HSV glycoproteins gB and gD, respectively. Two other clones, ES21 and ES37, were isolated from a peripheral blood sample from a different patient with genital HSV-2 infection and were found to be specific for the viral encoded gD. Following stimulation with their respective Ag, the cytokine secretion level for each T cell clone varied from low (clone ES21) to high (clone EB13). The pattern was consistent between experiments (Table I).

HSV immediate-early gene expression is required to induce inhibition of CD4⁺ T cell activation

We next sought to define viral gene function associated with this inhibitory effect. UV-inactivated HSV-2 did not induce inhibition of CD4⁺ T cell proliferation as compared with infectious HSV-2 (Table II). As such, we directed our efforts at evaluating viral-specific genes that were not contained in the viral particle. We used an HSV-2 ICP4 mutant (hr259). Since ICP4 is strictly required for expression of both early and late proteins, this mutant expresses only immediate-early proteins (ICP0, ICP6, ICP22, ICP27, and ICP47) (13). As clone EB47 is directed against the viral encoded gB, a late gene, we prevented any potential competition between soluble Ag and viral particles by preincubating the B-LCL with the glycoprotein before infection with the ICP4 mutant. As shown in Table II, B-LCL infection with the ICP4 mutant hr259 resulted in a strong inhibition of both the T cell proliferation and cytokine secretion. Although some IFN- was detected with HSV-2-infected B-LCL, the amount was significantly less than that induced by uninfected B-LCL. These data suggested that expression of an immediate-early HSV protein other than ICP4 was associated with this inhibition of the T cell activation.

We then tested whether the immediate-early protein ICP47, encoded by the HSV-1 US12 gene, could affect B-LCL APC function. As shown in Table III, B-LCL infected by the HSV-1 US12 deletion mutant (HV1.102) still lost their capacity to fully activate the CD4⁺ T cell clone EB47 in response to the purified gB. This inhibition was observed at the level of T cell proliferation as well as with cytokine secretion, suggesting that US12 gene expression is not required to induce the inhibition of the T cell activation.

View larger version (38K): [in this window] [in a new window]   FIGURE 1. B-LCL infection with HSV-1 US1 deletion mutant does not result in an inhibition of their stimulatory capacity. B-LCL infected overnight were used as stimulator cells to activate T cells in the presence of the purified soluble gB (clone EB47) or gD (clone ES37) or medium alone. Pulsed APC were obtained by incubating B-LCL with the respective purified glycoproteins before infection. Results shown are representative of three independent experiments. Error bars represent the SD of triplicate results. Cytokine secretion was measured at 24 h in pooled supernatants from triplicate cultures. The coefficient of variation for cytokine titration was <10%.

We next investigated whether the US1 gene product ICP22 was associated with the observed inhibition of the B-LCL APC function. The US1 gene was amplified by PCR from a DNA extract obtained from wild-type HSV-1 (strain F), and the PCR product was cloned into the eukaryotic cell expression vector pNS. Following amplification and purification, the expression vector was transfected into B-LCL using LipofectAMINE.

ICP22 protein expression was assessed using an intracellular staining technique. Uninfected, HSV-1-infected, and US1-transfected B-LCL were stained using a ICP22-specific rabbit antiserum and analyzed by flow cytometry. As shown in Fig. 2, following the same culture conditions as previously described for the T cell proliferation assay, ICP22 was detected in HSV-1-infected B-LCL. ICP22 was also detected with similar fluorescence intensity in all B-LCL after stable transfection and G418 selection. To assess whether ICP22 protein expression alone results in the observed inhibition, drug-resistant B-LCL expressing the ICP22 viral protein were used as APC in a T cell proliferation assay. As shown in Fig. 3, B-LCL transfected with the control vector coding for the isoform of the mouse CD8 protein were able to efficiently process and present soluble Ag to different CD4⁺ T cell clones. In contrast, a strong inhibition of T cell clone proliferation (Fig. 3A) as well as cytokine secretion (Fig. 3, B and C) was observed in the presence of the HSV-1 US1-transfected B-LCL.

View larger version (17K): [in this window] [in a new window]   FIGURE 2. ICP22 protein expression by HSV-1-infected or US1-transfected B-LCL. B-LCL were infected at an MOI of 10 and cultured overnight or transfected with the US1 pNS vector and grown in the presence of G418. After being permeabilized, cells were incubated with the rabbit antiserum (R77) specific for ICP22. Cells were then stained using an FITC-labeled goat anti-rabbit antiserum (solid line). Uninfected cells are shown as control (dashed line).

View larger version (31K): [in this window] [in a new window]   FIGURE 3. HSV-1 US1 expression inhibits B-LCL ability to stimulate CD4+ T cell clones. Various dilutions of B-LCL transfected with either pNS HSV-1 US1 () or the pNS CD8 control vector (•) were mixed with T cells in the presence of purified gB (clone EB47) or gD (clone EB13). The data are representative of four independent experiments with similar results. Error bars represent the SD of triplicate results. Cytokine secretion was measured at 24 h in pooled supernatants from triplicate cultures. The coefficient of variation for cytokine titration was <10%.

We further investigated whether ICP22 expression was affecting the B-LCL Ag presentation function at the level of Ag processing or presentation. We used a previously described HIV-specific CD4⁺ T cell clone (9G8), which recognizes a known peptide epitope in gp160 protein (15). Corresponding autologous B-LCL were transfected with either the HSV-1 US1 gene or the CD8 control vector. The cells were kept under G418 selection for 10 days to ensure that only transfected B-LCL were present in the remaining culture. The drug-resistant B-LCL were preincubated with the synthetic HIV-1 envelope peptide and then washed to prevent T-T cell activation during the proliferation assay. As seen in Fig. 4, US1-transfected B-LCL are again much less potent than vector control-transfected B-LCL in stimulating T cell proliferation (A) and cytokine secretion (B and C). Although some IFN- secretion could be detected, the level of secretion dropped quickly following the APC dilutions.

View larger version (21K): [in this window] [in a new window]   FIGURE 4. HSV-1 US1 expression inhibits T cell stimulation by synthetic peptide. B-LCL transfected with either pNS HSV-1 US1 or the pNS CD8 control vector were pulsed with the HIV-1 envelope epitope peptide (10 µg/ml) before being mixed with CD4+ T cells from the HIV-1-specific clone 9G8. Results are representative of five independent experiments. Error bars represent the SD of triplicate results. Cytokine secretion was measured at 24 h in pooled supernatants from triplicate cultures. The coefficient of variation for cytokine titration was <10%.

We also assessed whether HSV-1 US1 transfection in B-LCL induced modulation of cell surface proteins. Because transfected B-LCL were less potent in presenting synthetic peptide to a CD4⁺ T cell clone, we first looked at the expression of different MHC class II molecules (DR, DQ, and DP). As shown in Fig. 5, analysis by flow cytometry revealed no detectable difference between US1-transfected cells and the vector control transfectant. In humans, a decreased T cell response to recall Ags is often associated with depressed costimulatory receptor expression (18, 19). Therefore, we analyzed whether US1 transfection could affect the level of expression of the costimulatory molecules CD80 and CD86. Again, we could not detect any significant modulation in the cell surface expression level for either molecule.

View larger version (11K): [in this window] [in a new window]   FIGURE 5. Cell surface expression of MHC class II molecules and costimulatory molecules. B-LCL were transfected with either the pNS CD8 control vector (solid line) or the pNS HSV-1 US1 vector (dashed line). After 1 wk in culture under G418 selection, cells were stained for expression of MHC class II molecules (DR, DQ, and DP) or CD80 and CD86 costimulatory molecules. Results are representative of three independent experiments, all of which showed no discernible down-modulation of expression.

We next evaluated whether US1 gene expression could also affect CD4⁺ T cell-mediated lytic activity. For these experiments, we used the HIV-specific T cell clone 9G8 because of its high and stable lytic activity. B-LCL were infected with the US1 deletion virus or the corresponding repaired virus at a MOI of 10 and cultured overnight. The next day, the cells were incubated with the relevant synthetic peptide and washed before being used in a chromium release assay. As shown in Fig. 6A, B-LCL infected with the deletion mutant exhibited higher lytic activity than when infected with the repaired virus. In agreement with this observation, B-LCL transfected with HSV-1 US1 gene (Fig. 6B) also resulted in a similar decrease of the T cell lytic activity.

View larger version (23K): [in this window] [in a new window]   FIGURE 6. ICP22 expression protects target cells from CD4+ T cell-mediated lysis. T cells from the HIV-1 envelope-specific clone 9G8 were used in a chromium release assay against autologous B-LCL infected with either HSV-1 US1 deletion mutant or the corresponding repaired virus (A) or against B-LCL transfected with either pNS HSV-1 US1 or the pNS CD8 control vector (B). Target cells were incubated with the HIV-1 envelope synthetic peptide before being washed and mixed with T cells at various E:T ratios. Killing activity was also measured in a redirected lysis assay using FcR-positive P815 cells as target (C). Cells infected with either HSV-1 US1 deletion mutant or repaired virus were cultured overnight before being mixed with T cells at various E:T ratios in the presence of purified OKT3 Ab (1 µg/ml). This pattern of results was obtained in three other experiments. Error bars represent the SD of triplicate results.

Taken together, these results suggest that expression of the HSV-1 US1 gene in B-LCL or P815 cells lowers their susceptibility to CD4⁺ T cell-mediated lysis.

	Discussion

Top Abstract Introduction Materials and Methods Results Discussion References

 
One of the most central issues in the immunobiology of human herpesviruses is their ability to evade the immune response. Several studies have demonstrated the important role that both HSV-specific CD4⁺ and CD8⁺ T cells play in the clearance of virus from lesions and in the healing of these lesions. Several different mechanisms have been described by which the virus can interfere with the CD8⁺-mediated T cell response.

It is well documented that viral glycoprotein-specific CD4⁺ T cell clones proliferate and secrete lymphokines when stimulated with UV light-inactivated HSV in the presence of autologous PBL (20, 21, 22). To our knowledge, no virally encoded function has been previously identified that interferes with recognition of HSV-infected cells by human CD4⁺ T cells.

In this paper, we characterized a new immune evasion mechanism used by HSV to interfere with the CD4⁺-mediated cellular immune response. We have demonstrated that B-LCL infected by live HSV are strongly inhibited in their ability to induce CD4⁺ T cell clone proliferation and IL-2 or IFN- secretion. This inhibitory effect does not seem to be restricted to a particular type of CD4⁺ T cell clone or B-LCL line, as this result was reported for a total of five different clones from three different patients. Moreover, we have shown that T cell susceptibility to this inhibition was not restricted to HSV-specific T cell clones in that an HIV-specific clone also shows similar inhibition of its activation.

We reasoned that this effect on Ag presentation appeared to be related to early gene expression by the virus and demonstrated for HSV-1 that the immediate-early US1 gene was necessary and sufficient to induce the APC function inhibition. The HSV-1 ICP22, the product of the US1 gene, is a nucleotidylated and phosphorylated protein with properties of a transcriptional factor required for the expression of a subset of late viral genes (11). The coding domain of the US1 gene encodes two proteins, a full-length protein, ICP22, and a protein called US1.5 which is initiated from methionine 147 of ICP22 and which is colinear with the remaining portion of that protein. The two corresponding mRNAs are expressed by their own independent promoter (23). Our data do not allow us to determine which of either the ICP22 or US1.5 proteins is responsible for the APC function inhibition. Experiments to clarify that point are currently in progress.

Previous studies have reported that HSV-1 infection of monocytes and more recently of dendritic cells resulted in an impairment of their capacity to stimulate T cells. Following HSV-1 infection, human monocytes have been shown to lose their ability to induce resting T cell proliferation in response to superantigen (24). Similarly, HSV-1-infected human dendritic cells were unable to produce cytokines and were poorly stimulatory for allogeneic T cells (25). In this latter case, the virus was found to inhibit dendritic cell maturation. In our experiments, we have demonstrated that following the expression of the viral protein ICP22, HSV-1 is able to strongly inhibit the capacity of B-LCL to trigger an Ag-specific T cell activation. The inhibition is observed when the Ag is provided either as a soluble protein or as a synthetic peptide.

The function of MHC class II molecules is to sample exogenous Ags for presentation to CD4⁺ T cells. Newly synthesized MHC class II heterodimers associate with the invariant chain (Li) in the endoplasmic reticulum (26). Once the complex reaches the endosomal system, Li is degraded leaving the class II binding site available for binding antigenic peptide (27). The peptide loading process is facilitated by the presence of H2-DM molecules involved in the dissociation of Li fragments from the class II peptide binding groove (28). Previous studies have demonstrated that the principle means of presenting a soluble peptide on human B cells involves peptide loading directly onto surface class II molecules (29, 30). Therefore, exogenously supplied peptides bypass the intracellular Ag-processing pathway. As such, inhibition of the B-LCL ability to stimulate CD4⁺ T cell clones appears to be the result of an Ag presentation rather than an Ag processing deficiency. Although we have yet to define the exact mechanisms of APC inhibition by HSV, ICP22 protein expression did not affect cell surface expression of any of the MHC class II molecules (DR, DQ, and DP) or costimulatory molecules like CD80 and CD86. However, the possibility cannot be excluded that other costimulatory molecules, like the recently described B7h (31), could play a role in the observed inhibition.

During T cell activation, engagement of receptors triggers an active accumulation of molecules at the interface of the T cell and the APC, which then increases the overall amplitude and duration of T cell signaling. This process is actively driven by the cytoskeleton (32). It has been shown that following HSV-1 infection, an early viral function induces cytoskeletal alterations (33). Therefore, it is tempting to speculate that US1 can prevent the triggering of a full, sustained T cell response by interfering with cytoskeletal rearrangements that allow the relay of extracellular stimulatory signals to the nucleus. The observed inhibition of T cell activation could also result from US1 interference with a signal transduction pathway. This could be achieved by decreasing the expression of essential components of a pathway, as was recently described for another herpesvirus, the human CMV (34). Experiments to define these hypotheses appear to be warranted.

HSV-specific cytotoxic activity in a bulk T cell population isolated from skin lesion biopsy has been shown to be associated with CD8⁺ as well as CD4⁺ T cells. Lesion-infiltrating CD4⁺ T lymphocytes may exert immune control over HSV reactivation not only through the secretion of cytokines but also through their lytic activity. HSV-1 is known to be able to inhibit CD4-meditated lysis of human fibroblasts through a mechanism not yet completely understood (35). We have found that following either viral infection or US1 gene transfection, B-LCL become less susceptible to lysis by CD4⁺ T cells. Moreover, in a redirected lysis assay, we observed that HSV-1-infected P815 cells also become less susceptible to T cell-induced lysis. A recent report showing that HSV-1 ICP22 protein can partially prevent Hep-2 cell-induced apoptosis (36) could provide an explanation for our observations.

It is thus of great interest that in mice, HSV-1 US1 deletion mutant failed to cause death following intracerebral, i.p., or intravaginal inoculation (37) as compared with the parental virus. Our studies suggest an immunological explanation for this observation. The enhanced APC function associated with the deletion mutant would result in an enhanced host response and hence lower mortality.

In summary, we have shown that upon HSV infection, B-LCL are much less potent in inducing IFN- secretion in CD4⁺ T cells. In addition, the IL-2 secretion was also found to be strongly inhibited. We propose that, upon HSV infection, the overall reduction of cytokine levels may decrease the ability of the immune response to control viral spread at the onset of an outbreak because of the subsequent deficiency in antiviral cytokines, lower help for CD8⁺ T cells, or decreased local neutralizing Abs.

	Acknowledgments

 
We thank Mike Remington, Mary Shaughnessy, and Gail Barnum for specimen collection. The purified viral glycoproteins gB and gD and the HSV-2 ICP4 deletion mutant were kindly provided by Dr. Rae L. Burke and Dr. Michael Tigges (Chiron, Emeryville, CA). The E5 cell line was obtained from Dr. Neal DeLuca. HSV-1 US1, HSV-1 US3 deletion mutants, repaired viruses, and rabbit antiserum R77 were graciously provided by Dr. Bernard Roizman. The HSV-1 US12 deletion mutant was obtained from Dr. Jeffrey Vieira. pNS expression vector was provided by Dr. Osam Mazda. T cell clone 9G8 was obtained from Dr. Juliana McElrath. The HIV envelope epitope peptide was kindly provided by Dr. Bill Kwok. We thank Heather Parker for critical reading of this manuscript.

	Footnotes

 
¹ This work was supported by National Institutes of Health Grant AI 30731.

² Current address: Fred Hutchinson Cancer Research Center, 1100 Fairview Avenue N, Room D3-100, Seattle, WA 98109.

³ Address correspondence and reprint requests to Dr. Lawrence Corey, Fred Hutchinson Cancer Research Center, 1100 Fairview Avenue N, Room D3-100, Seattle, WA 98109.

⁴ Abbreviations used in this paper: ICP, infected cell protein; B-LCL, B-lymphoblastoid cell line; MOI, multiplicity of infection; US1, unique sequence 1; US3, unique sequence 3; US12, unique sequence 12; gB, glycoprotein B; gD, glycoprotein D; Li, invariant chain.

Received for publication November 15, 2000. Accepted for publication March 12, 2001.

	References

Top Abstract Introduction Materials and Methods Results Discussion References

 

1. Whitley, R. J., D. W. Kimberlin, B. Roizman. 1998. Herpes simplex viruses. Clin. Infect. Dis. 26:541.[Medline]
2. Zweerink, H. J., L. W. Stanton. 1981. Immune response to herpes simplex virus infections: virus-specific antibodies in sera from patients with recurrent facial infections. Infect. Immun. 31:624.[Abstract/Free Full Text]
3. Schmid, D. S., B. T. Rouse. 1992. The role of T cell immunity in control of herpes simplex virus. Curr. Top. Microbiol. Immunol. 179:57.[Medline]
4. Fruh, K., K. Ahn, H. Djaballah, P. Sempe, P. M. van Endert, R. Tampe, P. A. Peterson, Y. Yang. 1995. A viral inhibitor of peptide transporters for antigen presentation. Nature 375:415.[Medline]
5. Hill, A. B., B. C. Barnett, A. J. McMichael, D. J. McGeoch. 1994. HLA class I molecules are not transported to the cell surface in cells infected with herpes simplex virus types 1 and 2. J. Immunol. 152:2736.[Abstract]
6. Jerome, K. R., J. F. Tait, D. M. Koelle, L. Corey. 1998. Herpes simplex virus type 1 renders infected cells resistant to cytotoxic T-lymphocyte-induced apoptosis. J. Virol. 72:436.[Abstract/Free Full Text]
7. Matloubian, M., R. J. Concepcion, R. Ahmed. 1994. CD4⁺ T cells are required to sustain CD8⁺ cytotoxic T-cell responses during chronic viral infection. J. Virol. 68:8056.[Abstract/Free Full Text]
8. Mikloska, Z., V. A. Danis, S. Adams, A. R. Lloyd, D. L. Adrian, A. L. Cunningham. 1998. In vivo production of cytokines and (C-C) chemokines in human recurrent herpes simplex lesions: do herpes simplex virus-infected keratinocytes contribute to their production?. J. Infect. Dis. 177:827.[Medline]
9. Cunningham, A. L., P. A. Nelson, C. G. Fathman, T. C. Merigan. 1985. Interferon production by herpes simplex virus antigen-specific T cell clones from patients with recurrent herpes labialis. J. Gen. Virol. 66:249.[Abstract/Free Full Text]
10. Mikloska, Z., A. M. Kesson, M. E. Penfold, A. L. Cunningham. 1996. Herpes simplex virus protein targets for CD4 and CD8 lymphocyte cytotoxicity in cultured epidermal keratinocytes treated with interferon-. J. Infect. Dis. 173:7.[Medline]
11. Ogle, W. O., B. Roizman. 1999. Functional anatomy of herpes simplex virus 1 overlapping genes encoding infected-cell protein 22 and US1.5 protein. J. Virol. 73:4305.[Abstract/Free Full Text]
12. Purves, F. C., W. O. Ogle, B. Roizman. 1993. Processing of the herpes simplex virus regulatory protein 22 mediated by the UL13 protein kinase determines the accumulation of a subset of and mRNAs and proteins in infected cells. Proc. Natl. Acad. Sci. USA 90:6701.[Abstract/Free Full Text]
13. Smith, C. A., P. A. Schaffer. 1987. Mutants defective in herpes simplex virus type 2 ICP4: isolation and preliminary characterization. J. Virol. 61:1092.[Abstract/Free Full Text]
14. Koelle, D. M., H. Abbo, A. Peck, K. Ziegweid, L. Corey. 1994. Direct recovery of herpes simplex virus (HSV)-specific T lymphocyte clones from recurrent genital HSV-2 lesions. J. Infect. Dis. 169:956.[Medline]
15. Kent, S. J., P. D. Greenberg, M. C. Hoffman, R. E. Akridge, M. J. McElrath. 1997. Antagonism of vaccine-induced HIV-1-specific CD4⁺ T cells by primary HIV-1 infection: potential mechanism of vaccine failure. J. Immunol. 158:807.[Abstract]
16. Mazda, O., E. Satoh, K. Yasutomi, J. Imanishi. 1997. Extremely efficient gene transfection into lympho-hematopoietic cell lines by Epstein-Barr virus-based vectors. J. Immunol. Methods 204:143.[Medline]
17. Poggi, A., R. Biassoni, N. Pella, F. Paolieri, R. Bellomo, A. Bertolini, L. Moretta, M. C. Mingari. 1990. In vitro expansion of CD3/TCR^- human thymocyte populations that selectively lack CD3 gene expression: a phenotypic and functional analysis. J. Exp. Med. 172:1409.[Abstract/Free Full Text]
18. Yi-qun, Z., R. J. Joost van Neerven, A. Kasran, M. de Boer, J. L. Ceuppens. 1996. Differential requirements for co-stimulatory signals from B7 family members by resting versus recently activated memory T cells towards soluble recall antigens. Int. Immunol. 8:37.[Abstract/Free Full Text]
19. Barcy, S., M. Wettendorff, O. Leo, J. Urbain, M. Kruger, J. L. Ceuppens, M. de Boer. 1995. FcR cross-linking on monocytes results in impaired T cell stimulatory capacity. Int. Immunol. 7:179.[Abstract/Free Full Text]
20. Yasukawa, M., J. M. Zarling. 1984. Human cytotoxic T cell clones directed against herpes simplex virus- infected cells. I. Lysis restricted by HLA class II MB and DR antigens. J. Immunol. 133:422.[Abstract]
21. Yasukawa, M., J. M. Zarling. 1984. Human cytotoxic T cell clones directed against herpes simplex virus- infected cells. II. Bifunctional clones with cytotoxic and virus- induced proliferative activities exhibit herpes simplex virus type 1 and 2 specific or type common reactivities. J. Immunol. 133:2736.[Abstract]
22. Zarling, J. M., P. A. Moran, R. L. Burke, C. Pachl, P. W. Berman, L. A. Lasky. 1986. Human cytotoxic T cell clones directed against herpes simplex virus- infected cells. IV. Recognition and activation by cloned glycoproteins gB and gD. J. Immunol. 136:4669.[Abstract]
23. Carter, K. L., B. Roizman. 1996. The promoter and transcriptional unit of a novel herpes simplex virus 1 gene are contained in, and encode a protein in frame with, the open reading frame of the 22 gene. J. Virol. 70:172.[Abstract]
24. Hayward, A. R., G. S. Read, M. Cosyns. 1993. Herpes simplex virus interferes with monocyte accessory cell function. J. Immunol. 150:190.[Abstract]
25. Salio, M., M. Cella, M. Suter, A. Lanzavecchia. 1999. Inhibition of dendritic cell maturation by herpes simplex virus. Eur. J. Immunol. 29:3245.[Medline]
26. West, M. A., J. M. Lucocq, C. Watts. 1994. Antigen processing and class II MHC peptide-loading compartments in human B-lymphoblastoid cells. Nature 369:147.[Medline]
27. Lotteau, V., L. Teyton, A. Peleraux, T. Nilsson, L. Karlsson, S. L. Schmid, V. Quaranta, P. A. Peterson. 1990. Intracellular transport of class II MHC molecules directed by invariant chain. Nature 348:600.[Medline]
28. Sherman, M. A., D. A. Weber, P. E. Jensen. 1995. DM enhances peptide binding to class II MHC by release of invariant chain-derived peptide. Immunity 3:197.[Medline]
29. Monji, T., D. Pious. 1997. Exogenously provided peptides fail to complex with intracellular class II molecules for presentation by antigen-presenting cells. J. Immunol. 158:3155.[Abstract]
30. Nygard, N. R., K. S. Giacoletto, C. Bono, J. Gorka, S. Kompelli, B. D. Schwartz. 1994. Peptide binding to surface class II molecules is the major pathway of formation of immunogenic class II-peptide complexes for viable antigen presenting cells. J. Immunol. 152:1082.[Abstract]
31. Swallow, M. M., J. J. Wallin, W. C. Sha. 1999. B7h, a novel costimulatory homolog of B7.1 and B7.2, is induced by TNF. Immunity 11:423.[Medline]
32. Acuto, O., D. Cantrell. 2000. T cell activation and the cytoskeleton. Annu. Rev. Immunol. 18:165.[Medline]
33. Avitabile, E., S. Di Gaeta, M. R. Torrisi, P. L. Ward, B. Roizman, G. Campadelli-Fiume. 1995. Redistribution of microtubules and Golgi apparatus in herpes simplex virus-infected cells and their role in viral exocytosis. J. Virol. 69:7472.[Abstract]
34. Miller, D. M., Y. Zhang, B. M. Rahill, W. J. Waldman, D. D. Sedmak. 1999. Human cytomegalovirus inhibits IFN--stimulated antiviral and immunoregulatory responses by blocking multiple levels of IFN- signal transduction. J. Immunol. 162:6107.[Abstract/Free Full Text]
35. Posavad, C. M., J. J. Newton, K. L. Rosenthal. 1993. Inhibition of human CTL-mediated lysis by fibroblasts infected with herpes simplex virus. J. Immunol. 151:4865.[Abstract]
36. Aubert, M., J. O’Toole, J. A. Blaho. 1999. Induction and prevention of apoptosis in human HEp-2 cells by herpes simplex virus type 1. J. Virol. 73:10359.[Abstract/Free Full Text]
37. Poffenberger, K. L., A. D. Idowu, E. B. Fraser-Smith, P. E. Raichlen, R. C. Herman. 1994. A herpes simplex virus type 1 ICP22 deletion mutant is altered for virulence and latency in vivo. Arch. Virol. 139:111.[Medline]

This article has been cited by other articles:

				A. A. Chentoufi, X. Zhang, K. Lamberth, G. Dasgupta, I. Bettahi, A. Nguyen, M. Wu, X. Zhu, A. Mohebbi, S. Buus, et al. HLA-A*0201-Restricted CD8+ Cytotoxic T Lymphocyte Epitopes Identified from Herpes Simplex Virus Glycoprotein D J. Immunol., January 1, 2008; 180(1): 426 - 437. [Abstract] [Full Text] [PDF]

				L. G. Thebeau, S. P. Vagvala, Y. M. Wong, and L. A. Morrison B7 Costimulation Molecules Expressed from the Herpes Simplex Virus 2 Genome Rescue Immune Induction in B7-Deficient Mice J. Virol., November 15, 2007; 81(22): 12200 - 12209. [Abstract] [Full Text] [PDF]

				J. Neumann, A. M. Eis-Hubinger, and N. Koch Herpes Simplex Virus Type 1 Targets the MHC Class II Processing Pathway for Immune Evasion J. Immunol., September 15, 2003; 171(6): 3075 - 3083. [Abstract] [Full Text] [PDF]

				D. M. Koelle and L. Corey Recent Progress in Herpes Simplex Virus Immunobiology and Vaccine Research Clin. Microbiol. Rev., January 1, 2003; 16(1): 96 - 113. [Abstract] [Full Text] [PDF]

				J. Trgovcich, D. Johnson, and B. Roizman Cell Surface Major Histocompatibility Complex Class II Proteins Are Regulated by the Products of the {gamma}134.5 and UL41 Genes of Herpes Simplex Virus 1 J. Virol., June 14, 2002; 76(14): 6974 - 6986. [Abstract] [Full Text] [PDF]

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Barcy, S. Articles by Corey, L. Search for Related Content PubMed PubMed Citation Articles by Barcy, S. Articles by Corey, L.